Cytomx analysts
WebCytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline ... WebMar 30, 2024 · CytomX Therapeutics Stock Performance NASDAQ:CTMX opened at $1.54 on Thursday. The firm's fifty day simple moving average is $2.25 and its 200 day simple moving average is $1.84. CytomX Therapeutics has a twelve month low of $1.17 and a twelve month high of $3.02. Institutional Investors Weigh In On CytomX Therapeutics
Cytomx analysts
Did you know?
WebCTMX Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $2.48 … WebMar 2, 2024 · InvestorsObserveris giving CytomX Therapeutics Inc (CTMX) an Analyst Rating Rank of 15, meaning CTMX is ranked higher by analysts than 15% of stocks. The average price target for CTMX is $3.564 and analyst’s rate the stock as a Buy. Wall Street analysts are rating CTMX a Buy today.
WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has been assigned a consensus recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat reports. WebCompany Type For Profit. Phone Number 6503510353. CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. …
WebThe latest price target for CytomX Therapeutics ( NASDAQ: CTMX) was reported by Mizuho on Tuesday, March 28, 2024. The analyst firm set a price target for 2.00 expecting CTMX to rise to within 12 ... WebDXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security …
WebNov 7, 2024 · Taking into account the latest results, the eight analysts covering CytomX Therapeutics provided consensus estimates of US$71.5m revenue in 2024, which would reflect a chunky 16% decline on its...
WebApr 14, 2024 · The consensus estimate for Apple’s current full-year earnings is $6.05 per share. KeyCorp also issued estimates for Apple’s Q3 2024 earnings at $1.11 EPS, Q4 2024 earnings at $1.48 EPS, FY2024 ... ina garten oatmeal raisin pecan cookiesWebMar 27, 2024 · CytomX Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2024, missing the Zacks Consensus... in 529 tax deductionWebThe CytomX Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, … ina garten old fashioned banana cakeWebJan 6, 2024 · January 6, 2024, 1:46 PM · 3 min read Shares of CytomX Therapeutics CTMX were up 55.3% in after-market trading on Jan 5 after management announced its collaboration agreement with Moderna … ina garten oil and vinegar dressing recipeWebApr 14, 2024 · Analysts at StockNews.com initiated coverage on shares of DAVIDsTEA ( NASDAQ:DTEA – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating... in 510 bc what was the city of romeWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Rating) has received an average rating of "Hold" from the twelve analysts that are covering the firm, Marketbeat reports.One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the … ina garten old fashioned apple crisp recipeWebApr 13, 2024 · We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst … ina garten old fashioned banana cake recipe